Achiko
IPOPublic · Zurich · Founded 2018
- Headquarters
- Zurich
- Founded
- 2018
- Business Model
- B2B
- Website
- achiko.com
- Type
- Public
About
Achiko AG is a Zurich, Switzerland-headquartered company that pivoted from fintech into healthcare diagnostics, developing DNA aptamer-based rapid tests under its AptameX platform, including a saliva-based COVID-19 test and an in-development dengue fever diagnostic. The company operated a biotechnology division alongside a sister digital mobile health unit and maintained offices in Jakarta, Hong Kong, Singapore, and Seoul. As of 2026, Achiko AG is reported to be in liquidation.
Summary
Achiko is a Biotech company based in Zurich, founded in 2018. Investors include RiverFort Global Opportunities and SIX Swiss Exchange.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2022
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...